Cargando…
Cancer organoid applications to investigate chemotherapy resistance
In clinical practice, a large proportion of cancer patients receive chemotherapy, yet tumors persist or acquire resistance; removing this obstacle could help to lower the number of cancer-related fatalities. All areas of cancer research are increasingly using organoid technology, a culture technique...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792487/ https://www.ncbi.nlm.nih.gov/pubmed/36582205 http://dx.doi.org/10.3389/fmolb.2022.1067207 |
_version_ | 1784859644790833152 |
---|---|
author | Harada, Kenji Sakamoto, Naoya |
author_facet | Harada, Kenji Sakamoto, Naoya |
author_sort | Harada, Kenji |
collection | PubMed |
description | In clinical practice, a large proportion of cancer patients receive chemotherapy, yet tumors persist or acquire resistance; removing this obstacle could help to lower the number of cancer-related fatalities. All areas of cancer research are increasingly using organoid technology, a culture technique that simulates the in vivo environment in vitro, especially in the quickly developing fields of anticancer drug resistance, drug-tolerant persisters, and drug screening. This review provides an overview of organoid technology, the use of organoids in the field of anticancer drug resistance research, their relevance to clinical information and clinical trials, and approaches to automation and high throughput. |
format | Online Article Text |
id | pubmed-9792487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97924872022-12-28 Cancer organoid applications to investigate chemotherapy resistance Harada, Kenji Sakamoto, Naoya Front Mol Biosci Molecular Biosciences In clinical practice, a large proportion of cancer patients receive chemotherapy, yet tumors persist or acquire resistance; removing this obstacle could help to lower the number of cancer-related fatalities. All areas of cancer research are increasingly using organoid technology, a culture technique that simulates the in vivo environment in vitro, especially in the quickly developing fields of anticancer drug resistance, drug-tolerant persisters, and drug screening. This review provides an overview of organoid technology, the use of organoids in the field of anticancer drug resistance research, their relevance to clinical information and clinical trials, and approaches to automation and high throughput. Frontiers Media S.A. 2022-12-13 /pmc/articles/PMC9792487/ /pubmed/36582205 http://dx.doi.org/10.3389/fmolb.2022.1067207 Text en Copyright © 2022 Harada and Sakamoto. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Harada, Kenji Sakamoto, Naoya Cancer organoid applications to investigate chemotherapy resistance |
title | Cancer organoid applications to investigate chemotherapy resistance |
title_full | Cancer organoid applications to investigate chemotherapy resistance |
title_fullStr | Cancer organoid applications to investigate chemotherapy resistance |
title_full_unstemmed | Cancer organoid applications to investigate chemotherapy resistance |
title_short | Cancer organoid applications to investigate chemotherapy resistance |
title_sort | cancer organoid applications to investigate chemotherapy resistance |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792487/ https://www.ncbi.nlm.nih.gov/pubmed/36582205 http://dx.doi.org/10.3389/fmolb.2022.1067207 |
work_keys_str_mv | AT haradakenji cancerorganoidapplicationstoinvestigatechemotherapyresistance AT sakamotonaoya cancerorganoidapplicationstoinvestigatechemotherapyresistance |